carnitine has been researched along with Hepatitis B, Chronic in 8 studies
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment-naïve chronic hepatitis B patients receiving besifovir 90 mg (n=31), 150 mg (n=28) and entecavir 0." | 9.20 | Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. ( Ahn, SH; Cho, M; Han, KH; Kim, JA; Kweon, YO; Lai, CL; Lee, J; Lee, JW; Lee, KS; Park, NH; Sohn, JH; Um, SH; Yoon, SK; Yuen, MF, 2015) |
| " The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients." | 9.17 | Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. ( Bae, SH; Baek, YH; Cheong, JY; Cho, SW; Cho, YK; Choi, JY; Han, SY; Heo, J; Hwang, SG; Jun, DW; Jung, YJ; Kim, BI; Kim, HJ; Kim, HY; Kim, JK; Kim, SH; Kim, TY; Kim, W; Kwon, YO; Lee, BS; Lee, KS; Lee, YS; Lim, YS; Paik, YH; Park, SY; Rim, KS; Sohn, JH; Woo, HY, 2013) |
| "The outcome of hepatitis B virus (HBV) infection is significantly affected by host immune response; herein, we aim to dissect the effect of L-carnitine (L-Cn) on germinal center (GC)-related immune cells and the influence on the prognosis of HBV infection." | 8.12 | Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells. ( Chen, C; Fu, X; Gu, S; Guo, L; Hou, J; Li, X; Li, Y; Sun, J; Tang, L; Wang, W; Wen, C; Ye, G; Zhong, S; Zhou, Y, 2022) |
| "Carnitine status of children with chronic hepatitis B is not yet clear." | 7.72 | Plasma and liver carnitine levels of children with chronic hepatitis B. ( Selimoğlu, MA; Yağci, RV, 2004) |
| "Persistent antigen exposure during chronic hepatitis B infection leads to exhausted immune responses, thus impeding viral control." | 5.62 | High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. ( Chen, C; Chen, H; Fu, X; Gu, S; Hou, J; Jiang, D; Li, X; Li, Y; Tang, L; Ye, G; Zhong, S, 2021) |
| "Treatment-naïve chronic hepatitis B patients receiving besifovir 90 mg (n=31), 150 mg (n=28) and entecavir 0." | 5.20 | Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study. ( Ahn, SH; Cho, M; Han, KH; Kim, JA; Kweon, YO; Lai, CL; Lee, J; Lee, JW; Lee, KS; Park, NH; Sohn, JH; Um, SH; Yoon, SK; Yuen, MF, 2015) |
| " The purpose of this study is to identify the efficacy and safety of carnitine from entecavir combination therapy in Alanine aminotransferase (ALT) elevated Chronic Hepatitis B (CHB) patients." | 5.17 | Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. ( Bae, SH; Baek, YH; Cheong, JY; Cho, SW; Cho, YK; Choi, JY; Han, SY; Heo, J; Hwang, SG; Jun, DW; Jung, YJ; Kim, BI; Kim, HJ; Kim, HY; Kim, JK; Kim, SH; Kim, TY; Kim, W; Kwon, YO; Lee, BS; Lee, KS; Lee, YS; Lim, YS; Paik, YH; Park, SY; Rim, KS; Sohn, JH; Woo, HY, 2013) |
| "The outcome of hepatitis B virus (HBV) infection is significantly affected by host immune response; herein, we aim to dissect the effect of L-carnitine (L-Cn) on germinal center (GC)-related immune cells and the influence on the prognosis of HBV infection." | 4.12 | Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells. ( Chen, C; Fu, X; Gu, S; Guo, L; Hou, J; Li, X; Li, Y; Sun, J; Tang, L; Wang, W; Wen, C; Ye, G; Zhong, S; Zhou, Y, 2022) |
| "In chronic hepatitis B patients treated with peginterferon and adefovir, we identified strong associations of SLC16A9 gene variation and carnitine levels with HBsAg loss." | 3.80 | HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels. ( Chin, DJ; de Niet, A; Jansen, L; Kootstra, NA; Lopatin, U; Plat-Sinnige, MJ; Reesink, HW; Stelma, F; Takkenberg, RB; van Dort, KA; van Iperen, EP; Zwinderman, AH, 2014) |
| "Carnitine status of children with chronic hepatitis B is not yet clear." | 3.72 | Plasma and liver carnitine levels of children with chronic hepatitis B. ( Selimoğlu, MA; Yağci, RV, 2004) |
| "Persistent antigen exposure during chronic hepatitis B infection leads to exhausted immune responses, thus impeding viral control." | 1.62 | High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection. ( Chen, C; Chen, H; Fu, X; Gu, S; Hou, J; Jiang, D; Li, X; Li, Y; Tang, L; Ye, G; Zhong, S, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gu, S | 2 |
| Wang, W | 1 |
| Ye, G | 2 |
| Chen, C | 2 |
| Zhou, Y | 1 |
| Guo, L | 1 |
| Zhong, S | 2 |
| Li, X | 2 |
| Fu, X | 2 |
| Wen, C | 1 |
| Tang, L | 2 |
| Sun, J | 1 |
| Hou, J | 2 |
| Li, Y | 2 |
| Chen, H | 1 |
| Jiang, D | 1 |
| Jun, DW | 1 |
| Kim, BI | 1 |
| Cho, YK | 1 |
| Kim, HJ | 1 |
| Kwon, YO | 1 |
| Park, SY | 1 |
| Han, SY | 1 |
| Baek, YH | 1 |
| Jung, YJ | 1 |
| Kim, HY | 1 |
| Kim, W | 1 |
| Heo, J | 1 |
| Woo, HY | 1 |
| Hwang, SG | 1 |
| Rim, KS | 1 |
| Choi, JY | 1 |
| Bae, SH | 1 |
| Lee, YS | 1 |
| Lim, YS | 1 |
| Cheong, JY | 1 |
| Cho, SW | 1 |
| Lee, BS | 1 |
| Kim, SH | 1 |
| Sohn, JH | 3 |
| Kim, TY | 1 |
| Paik, YH | 1 |
| Kim, JK | 1 |
| Lee, KS | 3 |
| Lai, CL | 2 |
| Ahn, SH | 2 |
| Um, SH | 2 |
| Cho, M | 2 |
| Yoon, SK | 2 |
| Lee, JW | 2 |
| Park, NH | 2 |
| Kweon, YO | 2 |
| Lee, J | 2 |
| Kim, JA | 2 |
| Han, KH | 2 |
| Yuen, MF | 2 |
| Jansen, L | 1 |
| de Niet, A | 1 |
| Stelma, F | 1 |
| van Iperen, EP | 1 |
| van Dort, KA | 1 |
| Plat-Sinnige, MJ | 1 |
| Takkenberg, RB | 1 |
| Chin, DJ | 1 |
| Zwinderman, AH | 1 |
| Lopatin, U | 1 |
| Kootstra, NA | 1 |
| Reesink, HW | 1 |
| Selimoğlu, MA | 1 |
| Yağci, RV | 1 |
| Eskandari, GH | 1 |
| Polat, G | 1 |
| Tamer, L | 1 |
| Ersöz, G | 1 |
| Atik, U | 1 |
3 trials available for carnitine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carnitine; DNA, Viral; Drug Therapy, Combination; Enz | 2013 |
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
Topics: Adult; Alanine Transaminase; Antibodies, Viral; Antiviral Agents; Asian People; Carnitine; DNA, Vira | 2014 |
Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study.
Topics: Adult; Alanine Transaminase; Antiviral Agents; Carnitine; DNA, Viral; Female; Guanine; Hepatitis B e | 2015 |
5 other studies available for carnitine and Hepatitis B, Chronic
| Article | Year |
|---|---|
Hepatocyte-Derived L-Carnitine Restricts Hepatitis B Surface Antigen Loss Through an Immunosuppressive Effect on Germinal Center-Related Immune Cells.
Topics: Animals; Carnitine; Germinal Center; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; H | 2022 |
High L-Carnitine Levels Impede Viral Control in Chronic Hepatitis B Virus Infection.
Topics: Adult; Antiviral Agents; Carcinoma, Hepatocellular; Carnitine; Carnitine O-Palmitoyltransferase; CD4 | 2021 |
HBsAg loss in patients treated with peginterferon alfa-2a and adefovir is associated with SLC16A9 gene variation and lower plasma carnitine levels.
Topics: Adenine; Adult; Antiviral Agents; Carnitine; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; | 2014 |
Plasma and liver carnitine levels of children with chronic hepatitis B.
Topics: Adolescent; Antiviral Agents; Carnitine; Child; Child, Preschool; Drug Therapy, Combination; Female; | 2004 |
Serum L-carnitine levels and lipoprotein compositions in chronic viral hepatitis patients.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Choles | 2001 |